Chronischer Schmerz
Studienlage · Detail Systematic Review · Chronischer Schmerz · 2021

Cannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials

Gemischt GRADE Hoch 38 Zitate
Stichprobek = 13 Studien
n = 1.352 Pat.
Dauerunklar
KontrolleKontrollgruppen
EndpunktSchmerzintensität
Verblindungdoppelblind
DesignSystematic Review
Kernaussage

5 von 13 RCTs zeigten moderate analgetische Effekte von Cannabis für chronische Schmerzen, 8 zeigten keine signifikanten Unterschiede zur Kontrollgruppe.

Zusammenfassung

Rapid SR über k=13 RCTs (n=1.352) zu Cannabis bei chronischem Schmerz. Fünf Studien zeigten moderate analgetische Effekte, acht keine signifikanten Schmerzreduktionen vs. Kontrolle. Befund: moderate Evidenz für neuropathischen Schmerz, patientenberichteter Nutzen, relativ sicher mit wenigen schweren Nebenwirkungen. Schlussfolgerung: Cannabinoide haben potenzielle Rolle im chronischen Schmerzmanagement, inkonsistente Evidenz erfordert größere Studien.

P
PopulationErwachsene mit chronischem Schmerz, gepoolt n=1352
I
InterventionCannabis in verschiedenen Formulierungen (Cannabinoide)
C
KontrolleKontrollgruppen (aktive oder Placebo-Kontrolle)
O
Outcome5 von 13 RCTs zeigten moderate analgetische Wirkung; 8 RCTs zeigten keine signifikante Schmerzreduktion vs. Kontrolle
Vertrauen in die Evidenz
Hoch

Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.

Qualitätsprofil
Größe
Verblindung Doppelblind
Effektstärke Gemischt
Zitate / Jahr
Autoren
Longo R, Oudshoorn A, Befus D
DOI 10.1016/j.pmn.2020.11.006
Design: Systematic Review
Teilen
Abstract
Background: The high prevalence of inadequately managed chronic pain indicates the need for alternative and multimodal treatment options. Use of cannabinoids in medicine is becoming a growing area of interest, specifically in the context of chronic pain. The efficacy of cannabinoids for the treatment of chronic pain is not well established. Aims: The objectives of this rapid systematic literature review are to summarize the efficacy and secondary effects of cannabinoids for chronic pain management. Design: Rapid systematic review of randomized control trials. Participants: Individuals with chronic pain (n = 1352). Methods: Embase, Cochrane, PubMed, and CINAHL databases were searched. Inclusion criteria included cannabis of any formulation used to treat chronic pain of any origin. Results: Thirteen randomized controlled trials met the inclusion criteria. Five demonstrated moderate analgesic effects of cannabis for chronic pain, and eight concluded there were no significant impacts on pain in the cannabis-treated group versus the control group. Conclusions: Evidence on the efficacy of cannabinoids for chronic pain shows patient-perceived benefit but inconsistent other treatment effects. These findings indicate cannabinoids may have a modest analgesic effect for chronic neuropathic pain conditions, and that the use of cannabinoids is relatively safe, with few severe adverse events. This review concludes that cannabinoids may have a potential role in chronic pain management. Inconsistent evidence on the efficacy of cannabis to treat chronic pain indicates the need for more studies on a larger scale. Clinicians should draw on available evidence and consider cannabinoids as a potential approach to chronic pain management.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel